Cargando…
IKK inhibition by BMS-345541 suppresses breast tumorigenesis and metastases by targeting GD2(+) cancer stem cells
We have identified that the ganglioside GD2 is a marker for breast cancer stem cells (BCSCs), and that targeting the enzyme GD3 synthase (GD3S, which regulates GD2 biosynthesis) reduces breast tumorigenesis. The pathways regulating GD2 expression, and their anomalous functions in BCSC, are unclear....
Autores principales: | Battula, Venkata Lokesh, Nguyen, Khoa, Sun, Jeff, Pitner, Mary Kathryn, Yuan, Bin, Bartholomeusz, Chandra, Hail, Numsen, Andreeff, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514883/ https://www.ncbi.nlm.nih.gov/pubmed/28415808 http://dx.doi.org/10.18632/oncotarget.16294 |
Ejemplares similares
-
BMS-345541 inhibits airway inflammation and epithelial-mesenchymal transition in airway remodeling of asthmatic mice
por: Zhu, Xiaohua, et al.
Publicado: (2018) -
Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax
por: Berger, A, et al.
Publicado: (2013) -
Targeting NFκB signaling in GD2(+) BCSCs
por: Nguyen, Khoa, et al.
Publicado: (2017) -
GD2 and GD3 synthase: novel drug targets for cancer therapy
por: Sphyris, Nathalie, et al.
Publicado: (2015) -
Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2(+) breast cancer stem-like cells
por: Ly, Stanley, et al.
Publicado: (2021)